# EPI-7386 in Combination with Enzalutamide Compared with Enzalutamide Alone in Subjects with MCRPC

> **NCT05075577** · PHASE1,PHASE2 · TERMINATED · sponsor: **ESSA Pharmaceuticals** · enrollment: 77 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Enzalutamide
- **DRUG:** EPI-7386 with Enzalutamide

## Key facts

- **NCT ID:** NCT05075577
- **Lead sponsor:** ESSA Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-12-21
- **Primary completion:** 2024-10-31
- **Final completion:** 2025-01-14
- **Target enrollment:** 77 (ACTUAL)
- **Why stopped:** Study was terminated early due to a lack of improved efficacy.
- **Last updated:** 2025-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05075577

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05075577, "EPI-7386 in Combination with Enzalutamide Compared with Enzalutamide Alone in Subjects with MCRPC". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05075577. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*